A green nursery for biotech rooted in the Scanian soil

Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...

New study: Post-Covid symptoms are common even after mild Covid-19

According to researchers at the University of Gothenburg, loss of smell and taste, shortness of breath and chest symptoms are the most common complaints after a...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Study: An objective diagnosis of constant tinnitus may be possible

A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tin...

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Pfizer slutar sälja uppmärksammad genterapi

Pfizer kommer att avbryta utvecklingen och försäljningen av sin uppmärksammade och extremt dyra genterapi mot blödarsjuka, Beqvez. Orsaken uppges vara bristande efterfrågan.

Bio-Works

Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...

ZEISS Metrology Shop provides planning security

ZEISS Metrology Shop brings it all together.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap

From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered b...

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvan...

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Webinar: Medtech quality and regulatory compliance

This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...

Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"

The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – ...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...

Newly discovered gene variant linked to protection against abdominal obesity

American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the ...

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Mikael Kubista tillbaka med ny satsning – efter turbulenta avskedet

Entreprenören och forskaren Mikael Kubista startar ett nytt bolag. Nu är han också fri att kommentera händelseförloppet som ledde till att han förlorade ägandet...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Promising Alzheimer’s study data sends Bioarctic stock soaring

The drug candidate lecanemab from Swedish company Bioarctic significantly slowed down the deterioration in patients with early on-set Alzheimer’s, according to ...